July 06, 2026 09:55 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
China tests ballistic missile from nuclear submarine in Pacific: Australia, New Zealand respond | Baruipur horror: Main accused in alleged rape and murder of minor girl arrested; senior cops dissatisfied with handling of the case | Defence stocks jump after Rs 52,000 crore DAC approval sparks buying frenzy | 'Harry Kane is a great player': Donald Trump after England knocked Mexico out of the World Cup | 'Referee gave a lot against us': Harry Kane reacts after England's dramatic win over Mexico | England hold nerve with 10 men to knock out Mexico in five-goal World Cup classic | 'Why can't citizens protest against the government? They are being made slaves by slapping cases': Bombay HC slams Mumbai Police, quashes activist's externment | 'First he cheats on me...': Siya Goyal's old pub video goes viral amid probe into fiancé Ketan Agarwal's alleged murder | Ronaldo's goal, Ramos' last-gasp winner send Portugal past Croatia, set up Spain clash | India-US trade deal almost done! Piyush Goyal hints at breakthrough
Moderna Vaccine

US approves Moderna COVID-19 vaccine

| @indiablooms | Dec 19, 2020, at 02:58 pm

Washington: The United States has approved Moderna's COVID-19 vaccine, paving the way for the release of millions of doses.

It is now the second vaccine to get approval.

US President Donald Trump tweeted: " Congratulations, the Moderna vaccine is now available!"

 The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the second vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the U.S. for use in individuals 18 years of age and older, read the statement issued by U.S. Food and Drug Administration.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M. Hahn, M.D. 

“Through the FDA’s open and transparent scientific review process, two COVID-19 vaccines have been authorized in an expedited timeframe while adhering to the rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization that the American people have come to expect from the FDA," Hahn said.

"These standards and our review process, which are the same we have used in reviewing the first COVID-19 vaccine and intend to use for any other COVID-19 vaccines, included input from independent scientific and public health experts as well as a thorough analysis of the data by the agency’s career staff," said Stephen M. Hahn.  

The FDA has determined that the Moderna COVID-19 Vaccine has met the statutory criteria for issuance of an EUA. 
The totality of the available data provides clear evidence that the Moderna COVID-19 Vaccine may be effective in preventing COVID-19.

The data also show that the known and potential benefits outweigh the known and potential risks—supporting the company’s request for the vaccine’s use in people 18 years of age and older.

In making this determination, the FDA can assure the public and medical community that it has conducted a thorough evaluation of the available safety, effectiveness, and manufacturing quality information.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.